Microfluidic engineering for organoid formation, cultivation, and sensing www.frontiersin.org Nov. 21, 2026, 5:13 a.m.
Microfluidic engineering represents a transformative approach to organoid development and analysis, integrating advanced fluidic systems with three-dimensional tissue culture technologies. This comprehensive review, published in Frontiers in Bioengineering and Biotechnology by Kushnir and colleagues, examines how microfluidic devices facilitate organoid formation, cultivation, and real-time sensing capabilities. The research synthesizes emerging applications of organoid-on-a-chip platforms, which leverage precisely controlled microenvironments to replicate physiological conditions more accurately than conventional methods. Key focus areas include microfluidic tissue engineering, on-chip sensing technologies, and vascularization strategies essential for creating functional organ models. These innovations enable sophisticated drug screening protocols by providing more predictive human tissue models, reducing reliance on traditional animal testing. The integration of microfluidics with organoid technology offers significant advantages for pharmaceutical development, personalized medicine, and disease modeling. By combining spatial control, nutrient delivery, and waste removal through microfluidic channels, researchers can generate more physiologically relevant organoids. This advancement has profound implications for accelerating drug discovery timelines, improving therapeutic efficacy predictions, and potentially revolutionizing preclinical testing paradigms across the biomedical industry.
Chinese Drug Shows Benefit in HER2-Low Breast Cancer www.medpagetoday.com Nov. 21, 2026, 5:12 a.m.
A Chinese phase III trial demonstrated that trastuzumab rezetecan, an investigational antibody-drug conjugate targeting HER2, significantly improved progression-free survival in patients with HER2-low metastatic breast cancer compared to physician's choice chemotherapy. The HORIZON-Breast06 trial showed median PFS of 16.4 versus 6.8 months in the overall population and 16.6 versus 6.8 months in chemotherapy-naive patients, with consistent benefits regardless of hormone receptor status. Twelve-month overall survival rates favored trastuzumab rezetecan at 90.6% versus 81.4%. The drug links a HER2-targeted monoclonal antibody to a potent topoisomerase I inhibitor and is already approved in China for non-small cell lung cancer and colorectal cancer. However, experts note that trastuzumab deruxtecan, an FDA-approved competitor showing similar efficacy, remains the preferred option in countries where available. The findings, presented at ESMO in Madrid and published in JAMA, underscore the need for head-to-head comparisons and strategic treatment sequencing to define trastuzumab rezetecan's role in the evolving breast cancer treatment landscape.
What Will It Take To Turn CGT Innovation Into Market Success? www.cellandgene.com Nov. 21, 2026, 5:12 a.m.
Cell and gene therapy (CGT) innovations face significant hurdles beyond regulatory approval, as industry leaders discussed at Advanced Therapies USA 2026 in Boston. During a panel moderated by Gwendolyn Binder of Cabaletta Bio, executives from KSQ Therapeutics, Nanoscape Therapeutics, Iovance Biotherapeutics, Sumitomo Pharma America, and University College London emphasized that successful CGT commercialization requires integrated strategies encompassing development, manufacturing, reimbursement, diagnosis, and delivery infrastructure. The discussion revealed that payers increasingly demand evidence of durable clinical benefit and disease course modification before approving one-time therapies, particularly in novel categories lacking established precedents. Nanoscape Therapeutics highlighted how four years of follow-up data from its randomized trial for degenerative retinal disease strengthens its value proposition by demonstrating vision preservation and restoration of patient independence. Similarly, Sumitomo Pharma leveraged 25 years of clinical experience from Duke University to establish durability for its tissue-based therapy for ultra-rare congenital immune deficiency. Industry leaders underscored that engaging payers, regulators, and patient advocacy groups early in development is essential for translating promising science into market-viable therapies that genuinely reach patients.
Keytruda biosimilars are coming — but they face an uphill battle www.biopharmadive.com Nov. 21, 2026, 5:12 a.m.
Merck's Keytruda, the world's bestselling cancer drug generating $31.7 billion in 2025, faces an approaching patent cliff with key expirations beginning in 2028. The FDA has accepted the first biosimilar application, FYB206 developed by Formycon and commercialized by Zydus Lifesciences, which could receive approval as early as Q3 2027. Approximately a dozen other biosimilar candidates are in development. Despite FDA initiatives like the Biosimilars Action Plan to facilitate market entry, biosimilars face significant barriers to competitive success. Industry experts warn that complex financial arrangements between branded manufacturers, pharmacy benefit managers, insurers, and hospitals create systemic incentives favoring established products over newcomers. These hidden deals may prevent biosimilars from meaningfully reducing consumer costs, even after regulatory approval. With an estimated 118 biologic medicines worth $232 billion in sales approaching patent expiration by 2034, the structural obstacles facing Keytruda biosimilars illustrate broader challenges within the pharmaceutical supply chain that could limit competition's ability to deliver anticipated savings.
CAR-T Therapy Cost 2026: US vs China vs Korea vs Turkey ($30K-$475K) cancercaree.com Nov. 21, 2026, 5:12 a.m.
# Professional Summary This comprehensive health-economics analysis examines the true total cost of care (TCOC) for CAR-T cell therapy across seven countries, challenging the common misconception that significant savings justify international travel for treatment. The study demonstrates that while base drug costs vary substantially—from approximately $30,000–$80,000 in China to $400,000 in the United States—the actual financial differential shrinks dramatically when accounting for hidden expenses including six to eight weeks of international accommodation, companion travel costs, potential intensive care management of Cytokine Release Syndrome, and lost income. The realistic cost disparity between countries typically amounts to 60–70%, not the 90% commonly cited. The analysis employs rigorous health-economics methodology, including incremental cost-effectiveness ratio calculations (ICER), establishing that ratios below $100,000–$150,000 per quality-adjusted life year generally represent cost-effective interventions. Critical barriers to cross-border CAR-T therapy include clinical-trial eligibility requirements, visa processing delays of 4–8 weeks, disease urgency, patient mobility constraints, and mandatory companion care requirements. The research emphasizes that clinical trial screening and logistical considerations often represent the primary financial gatekeepers, superseding simplified drug-cost comparisons. Financial optimization should never compromise clinical safety or introduce treatment delays in rapidly progressing malignancies.
Investigating Novel Immunotherapy Targets in Metastatic RCC www.targetedonc.com Nov. 18, 2026, 2:11 p.m.
Researchers at City of Hope are investigating novel immunotherapy targets to address treatment resistance in metastatic renal cell carcinoma (mRCC), particularly for patients whose disease progresses after immunotherapy-containing regimens. At the 2026 ESMO Congress, Dr. Rahul Winayak presented findings examining four emerging therapeutic targets: GPR65, HPK1, ENPP3, and CD70. GPR65 senses acidity within the tumor microenvironment and promotes immunosuppression in clear cell RCC, offering a novel intervention point. HPK1 functions as an intracellular T-cell activation regulator, providing an alternative checkpoint approach beyond established surface pathways. ENPP3, a surface protein highly expressed in clear cell RCC, is being targeted through bispecific T-cell engagers designed to facilitate tumor cell and T-cell interaction to enhance antitumor immunity. CD70 is being explored through chimeric antigen receptor (CAR) T-cell therapies. These targets represent distinct biological mechanisms for combating tumor growth and immune evasion. As treatment resistance remains a significant challenge in mRCC management, investigating targets with diverse functional roles could substantially expand therapeutic options for patients requiring additional treatment strategies. Further clinical investigation is essential to establish safety and efficacy profiles for these emerging approaches.
Keytruda biosims are coming — but they face an uphill battle www.pharmavoice.com Nov. 18, 2026, 2:11 p.m.
Merck's blockbuster immunotherapy Keytruda faces biosimilar competition as its patent expires in 2028, with the FDA accepting its first biosimilar application, FYB206, in October, potentially approving it by Q3 2027. Approximately a dozen other Keytruda biosimilars are in development for what generated $31.7 billion in 2025 revenue. However, industry experts warn biosimilars face significant market barriers despite FDA support through its Biosimilars Action Plan. Strategic agreements between branded manufacturers, pharmacy benefit managers, insurers, and hospitals create financial incentives favoring established products, potentially preventing competitive pricing benefits. FYB206, developed by Formycon and commercialized by Zydus Lifesciences, avoided a comparative phase 3 efficacy trial, reducing costs and accelerating development. The broader concern extends beyond Keytruda—approximately 118 biologic medicines worth $232 billion in potential sales lose patent protection by 2034, yet industry experts contend that without addressing the complex web of anti-competitive agreements throughout the pharmaceutical supply chain, biosimilar market penetration will remain limited and consumer cost savings unlikely.
Future of AI in Healthcare: 7 Trends Reshaping Medicine by 2030 www.spaceo.ai Nov. 18, 2026, 2:10 p.m.
The artificial intelligence healthcare market is experiencing dramatic acceleration, projected to grow from $56.01 billion in 2026 to $1.03 trillion by 2034 at a 43.96% compound annual growth rate. What were pilot programs just two years ago—such as ambient clinical documentation—have become standard infrastructure across US hospitals. This trajectory reflects a broader pattern where emerging AI technologies transition from experimental to production deployment within 24-36 months. The article identifies seven key trends reshaping healthcare AI through 2030, including agentic AI systems, multimodal diagnostics, digital twins, and federated learning. Currently, most AI systems produce single outputs requiring human review and action. The industry is shifting toward agentic AI platforms that autonomously make sequential decisions, coordinate multi-step workflows, and manage clinical processes without intervention at each step. UpDoc has achieved FDA 510(k) clearance for UpDoc V1.0, described as the first FDA-cleared agentic clinical AI platform, which autonomously manages insulin titration for type 2 diabetes patients. Major healthcare IT vendors including Oracle, Epic, and Cerner are embedding AI capabilities into their platforms, signaling widespread organizational readiness for this transformation.
Editorial: Precision Medicine and Targeted Therapies in Gastrointestinal and Genitourinary Solid Tumors www.frontiersin.org Nov. 18, 2026, 2:10 p.m.
The management of gastrointestinal and genitourinary malignancies is undergoing significant transformation through advances in comprehensive genomic profiling, molecular diagnostics, and biomarker-guided drug development. Contemporary practice now incorporates actionable biomarkers including HER2, PD-L1, mismatch-repair/microsatellite-instability status, and CLDN18.2, with broad next-generation sequencing increasingly used to identify additional targetable alterations. Recent American Society of Clinical Oncology guidance emphasizes obtaining predictive biomarker results early to inform treatment selection in advanced gastroesophageal cancers. The field is evolving toward dynamic precision oncology, leveraging circulating tumor DNA and liquid-biopsy approaches for minimally invasive genomic profiling, treatment selection, and longitudinal disease monitoring. Repeat molecular testing proves valuable when tumors evolve under therapeutic pressure or initial testing proves uninformative. Integration of genomic, transcriptomic, immune, and multi-omic data further improves tumor characterization and enables adaptive treatment strategies. A comprehensive research topic comprising 39 articles examines molecular biomarkers, targeted therapies, immunotherapy, and translational technologies, illustrating the critical shift from single-biomarker matching to multidimensional, adaptive precision oncology approaches for improved patient outcomes.
The Next Frontier of Cellular Therapy in Oncology www.cancernetwork.com Nov. 18, 2026, 2:10 p.m.
The National Immune Cell Effector Therapy (ICE-T) Symposium convened in September 2025 in Kansas City, bringing together clinicians and researchers to advance cellular immunotherapy in oncology. The meeting addressed chimeric antigen receptor (CAR) T-cell therapy and bispecific T-cell engagers, highlighting their expanding applications in multiple myeloma, lymphomas, and autoimmune conditions such as systemic lupus erythematosus. A notable presentation by researchers from the University of Kansas Medical Center examined previously underrecognized neurologic toxicities associated with BCMA-directed CAR T-cell therapies, specifically ciltacabtagene autoleucel (cilta-cel) and idecabtagene vicleucel (ide-cel). Analyzing 128 patients treated between December 2019 and December 2024—including 82 receiving cilta-cel and 46 receiving ide-cel—the study identified delayed, parkinsonian-like symptoms distinct from the well-characterized immune effector cell-associated neurotoxicity syndrome (ICANS). These findings underscore an emerging neurotoxicity spectrum beyond traditional frameworks, requiring heightened clinical vigilance. The symposium collectively emphasized advancing cellular therapy safety, scalability, and equitable access while refining toxicity recognition and management strategies.
‘Mimicking’ fasting for longevity and disease prevention hsph.harvard.edu Nov. 16, 2026, 12:20 p.m.
The FMD—which is low-sugar, low-protein, and high in healthy fats—came out of the Longo lab’s discoveries about nutrient-sensing pathways and how those pathways influence aging and age-related diseases. It’s now available in commercial kits which include pre-portioned soups, drinks, supplements, and snacks. (Longo consults for the company that makes them but donates his fees to charity.) The diet has been carefully formulated based on extensive research and would be difficult for individuals to safely replicate on their own, according to the company. Longo also wrote a book on his longevity diet aimed at the general public.
Le secteur pharmaceutique : quelle est la place de l’innovation dans le développement de nouveaux médicaments ? abgi-france.com Nov. 14, 2026, 5:13 a.m.
The global pharmaceutical market generated 1.482 trillion dollars in 2022 and is projected to reach 1.9 trillion dollars by 2027, exceeding pre-pandemic forecasts. The European Medicines Agency received 100 marketing authorization applications in 2022, approving 89, including 41 for new active substances. France ranks as the world's fifth pharmaceutical actor with 2.8 percent market share, conducting 507 clinical trials in 2022. To strengthen its position, France launched the Innovation Santé 2030 plan in 2021, mobilizing over 7 billion euros to establish France as the leading innovative and sovereign nation in healthcare. This strategic initiative addresses rising chronic diseases, long-term conditions, and multiple pathologies driven by population aging and emerging risk factors. Recent research from Leem (Les entreprises du médicament) reveals that 63 percent of French citizens believe pharmaceutical advances will lead healthcare progress by 2030. Pharmaceutical innovation, incorporating advanced technologies and biotechnology startup collaborations, is essential for developing superior medications. These innovations have enabled treatment of previously incurable diseases including tuberculosis and Chagas disease while improving patient quality of life through curative and palliative therapies.
Inhibiteurs des voies de transduction : Comprendre ces thérapies ciblées www.arcagy.org Nov. 14, 2026, 5:12 a.m.
# Summary Signal transduction pathway inhibitors represent a critical therapeutic approach targeting aberrant intracellular signaling in cancer. The phosphatidylinositol 3-kinase (PI3K) pathway, frequently dysregulated in tumor cells, plays a central role in resisting apoptosis, promoting cell proliferation, and enabling angiogenesis. Key components include PI3K itself, its downstream effector AKT kinase, and mTOR (mammalian Target of Rapamycin), a central controller of cell growth. PTEN functions as a crucial tumor suppressor, negatively regulating PI3K activity; its loss through mutations drives oncogenic signaling. mTOR regulates cell cycle progression and cellular growth through S6K and 4E-BP1 pathways. Several therapeutic agents have been developed targeting these pathway components. Alpelisib inhibits PI3K and is approved for breast cancer, while copanlisib targets follicular lymphoma. Duvelisib and idelalisib inhibit PI3K variants with indications in chronic lymphocytic leukemia and follicular lymphoma. These inhibitors address the molecular mechanisms underlying cancer cell survival and proliferation, offering targeted treatment options for patients with pathway-dependent malignancies.
L'hormonothérapie, une option pour traiter certains cancers du sein www.arcagy.org Nov. 14, 2026, 5:11 a.m.
Hormone therapy represents a significant treatment option for hormone receptor-positive breast cancers, which express functional estrogen and/or progesterone receptors on their cancer cells. These hormonally-dependent tumors, classified as luminal type, generally carry a better prognosis. Hormone therapy works by depriving cancer cells of the hormones necessary for growth or by blocking estrogen receptors, with treatment approaches varying based on menopausal status at diagnosis. Three primary hormone therapy modalities are currently available. The treatment can be administered at different disease stages, most commonly as adjuvant therapy following chemotherapy and radiotherapy. Tamoxifen-based hormone therapy typically begins after radiotherapy due to potential skin and lung toxicity risks, while aromatase inhibitors can be initiated concurrently with radiotherapy. Neoadjuvant therapy may benefit postmenopausal women with low-proliferation, HER2-negative, receptor-positive tumors, while advanced disease patients, particularly elderly women, may benefit from complementary hormone therapy. Understanding hormone resistance, defined by disease recurrence beyond 24 months of adjuvant therapy or clinical stabilization under treatment, remains crucial for optimizing therapeutic outcomes.
Exosome based nanocarriers enabling effective treatment of antimicrobial resistant infections through improved delivery and clinical potential | Discover Nano link.springer.com Nov. 14, 2026, 5:11 a.m.
# Summary Researchers have developed exosome-based nanocarriers as a novel therapeutic approach to combat antimicrobial-resistant infections, addressing a critical global health challenge. Exosomes, naturally occurring extracellular vesicles derived from cells, serve as biocompatible drug delivery systems that can effectively transport antimicrobial agents to infected sites while minimizing systemic toxicity. This review, published in November 2026 in Discover Nano, examines how these nanocarrier systems enhance drug efficacy against resistant pathogens through improved cellular penetration and targeted delivery mechanisms. The technology demonstrates significant clinical potential by overcoming traditional barriers that limit conventional antibiotic effectiveness, including poor bioavailability and bacterial resistance mechanisms. Exosome-based nanocarriers represent a promising alternative to standard antimicrobial therapies, offering enhanced therapeutic outcomes while reducing adverse effects. This advancement is particularly significant given the urgent need for innovative solutions to antimicrobial resistance, which poses substantial risks to modern healthcare systems and patient outcomes globally.
Pour une filière publique du médicament et des produits de santé institutlaboetie.fr Nov. 14, 2026, 5:11 a.m.
Modern societies face escalating health challenges including cancer, cardiovascular disease, antimicrobial resistance, chronic illnesses, and emerging infectious diseases, compounded by climate change. These conditions are not merely individual accidents but are substantially produced by capitalist and extractivist socioeconomic systems that perpetuate colonial relationships between developed and developing nations, disproportionately affecting certain social groups and territories. Healthcare systems, already weakened by decades of public disinvestment, austerity measures, and advancing privatization, must prepare for rising patient care demands. In response, a dual approach is necessary: prevention addressing social, economic, environmental, and political causes of illness, and treatment addressing declared health conditions. This analysis focuses specifically on pharmaceutical and health product policies as essential components of strengthening public healthcare systems, emphasizing the need for robust public investment rather than privatization to ensure equitable, sustainable responses to contemporary health crises.
Antimicrobial Resistance Threats Reports | Antimicrobial Resistance www.cdc.gov Nov. 10, 2026, 11:18 p.m.
Antimicrobial resistance remains a critical public health emergency threatening lives while straining healthcare, agriculture, and economic resources. The CDC released its 2026 Antimicrobial Resistance Threats Report, representing the most comprehensive assessment of drug-resistant pathogen impacts in the United States to date. The report categorizes 19 bacterial and fungal pathogens by threat level—urgent, serious, and concerning—while monitoring six additional pathogens on a Watch List as emerging threats. According to the 2026 update, drug-resistant bacteria and fungi cause approximately 9.7 million infections and 50,800 deaths annually in the U.S. To enhance accessibility and enable more frequent updates, CDC transitioned the report from a printed format to a dynamic website platform. The 2026 update employed revised methodologies and data sources, making direct comparisons to previous reports inadvisable except for Candida auris. Building on the legacy of the 2013 AR Threats Report, which initially documented 2 million infections and 23,000 deaths, this updated assessment provides policymakers and stakeholders with critical data to guide investments and interventions in combating antimicrobial resistance.
Nanomaterials Reshaping Tumor Metabolism: A New Frontier to Overcome T Cell Exhaustion www.dovepress.com Nov. 10, 2026, 11:18 p.m.
Researchers from Wuxi Taihu University have published a comprehensive review in the International Journal of Nanomedicine examining how nanomaterials can reshape tumor metabolism to overcome immunotherapy resistance. The study, led by Xiaoyan Zhu and colleagues, addresses a critical challenge in cancer treatment: metabolically hostile tumor microenvironments suppress T cell function through interconnected mechanisms including lactate and adenosine accumulation, lipid dysregulation, glucose and amino acid deprivation, and hypoxia. Rather than acting independently, these stressors form a reinforcing network that drives T cell exhaustion and causes checkpoint blockade to fail. The authors map nanomaterial-based solutions onto this metabolic network, including catalytic nanomaterials for degrading lactate and adenosine, lipid-modulating formulations, mitochondria-targeted delivery systems, amino acid replenishment approaches, and hypoxia-relieving designs. Key design principles—tissue targeting, stimuli-responsive release, and rational combination strategies—determine clinical effectiveness. Preclinical evidence suggests that nanomaterial-mediated metabolic remodeling can convert immunosuppressive environments into immune-supportive niches, potentially restoring exhausted T cell function. The review identifies critical gaps limiting clinical translation, particularly the need for subset-level evaluation to distinguish reversible versus irreversible T cell dysfunction states.
Classified, Authorised, Provided, Prescribed: A Global Regulatory Comparison Of Regenerative Medicine In The United States, European Union, Japan And Brazil-And The Legitimate Space Of The Curious Physician www.genesispub.org Nov. 10, 2026, 11:17 p.m.
This peer-reviewed study by Kume and colleagues examines the complex regulatory landscape governing regenerative medicine across four major jurisdictions: the United States, European Union, Japan, and Brazil. The research addresses how regenerative medicine interventions are governed through four distinct regulatory mechanisms: classification of the intervention, market authorization, authorization to investigate or provide services, and professional prescription rights. The authors investigate the legitimate regulatory space available to physicians practicing regenerative medicine within each region's framework. By conducting a comparative analysis of these four regulatory systems, the study illuminates how different approaches to oversight affect clinical practice and innovation in regenerative medicine. This comparative regulatory analysis is significant for healthcare professionals, regulatory bodies, and industry stakeholders seeking to understand the varying pathways for developing and delivering regenerative medicine therapies globally. The work provides clarity on how regulatory classifications and authorization requirements differ internationally, which has important implications for clinical implementation and cross-border medical practice in this rapidly evolving field.
Rising to the challenge: CAR T’s future in haematological cancers www.iqvia.com Nov. 10, 2026, 11:17 p.m.
Chimeric antigen receptor (CAR) T-cell therapies represent a transformative approach to treating haematological cancers, capable of delivering lasting remissions through single infusions. The field advanced dramatically following Emily Whitehead's pioneering case in 2012, when she became the first ALL patient to receive CAR T therapy and achieved sustained cancer-free survival. Traditional CAR T treatment involves extracting a patient's T-cells, genetically engineering them to express CARs targeting cancer-specific antigens, expanding them ex vivo, and reinfusing them to destroy malignant cells. Since the first commercial approval in 2017, seven CAR T therapies have been FDA and EMA approved, primarily for B-cell lymphomas, leukaemias, and multiple myeloma. Clinical development has progressively moved CAR T earlier in treatment sequences—from fourth-line to second-line indications—as evidence demonstrated improved efficacy and outcomes in patients with fewer treatment-related complications. The field continues expanding into solid tumours and autoimmune diseases like lupus. Despite these advances, significant clinical and commercial challenges remain as CAR T administration widens, requiring ongoing innovation to optimize patient outcomes and accessibility.